S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
How to Invest in AI's Fast-Growing Market (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
How to Invest in AI's Fast-Growing Market (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
How to Invest in AI's Fast-Growing Market (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
10 Ways Entrepreneurs Can Navigate a Down Economy
The Largest Ever Technology Wave Is Coming! (Ad)
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
A Woman Co-founder's Guide to Empowering Women in the Workplace and Advocating for Gender Equality
The Largest Ever Technology Wave Is Coming! (Ad)
Open vs. Anonymous Employee Feedback — Which is Better?
South African president appoints judge to oversee weapons-for-Russia inquiry
How to Invest in AI's Fast-Growing Market (Ad)
3 Cheap (and Tax-Free) Dividends That Love Debt-Ceiling Drama
Poland imposes sanctions on 365 Belarusians over 'draconian' verdict against journalist
NASDAQ:OPNT

Opiant Pharmaceuticals (OPNT) Earnings Date, Estimates & Call Transcripts

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$20.03
▼
$21.10
52-Week Range
N/A
Volume
562,700 shs
Average Volume
77,920 shs
Market Capitalization
$108.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

OPNT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

OPNT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Opiant Pharmaceuticals Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20231($2.14)($2.14)($2.14)
Q2 20231($2.25)($2.25)($2.25)
Q3 20231$0.00$0.00$0.00
Q4 20231($0.88)($0.88)($0.88)
FY 20234($5.27)($5.27)($5.27)

Opiant Pharmaceuticals Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/14/2022Q3 2022($1.51)($1.93)($0.42)($1.93)$4.43 million$0.17 million
8/11/2022Q2 2022($1.29)($2.31)($1.02)($2.31)$5.37 million$3.89 million
5/10/2022Q1 2022($0.75)($2.43)($1.68)($2.43)$7.13 million$4.47 million    
3/15/2022Q4 2021$0.10$0.11+$0.01$0.11$13.68 million$13.80 million    
11/11/20219/30/2021$0.15$0.56+$0.41$0.56$12.45 million$16.34 million    
8/5/20216/30/2021($0.28)$0.31+$0.59$0.31$8.01 million$11.26 million  
5/11/20213/31/2021($0.71)($0.66)+$0.05($0.66)$5.29 million$6.39 million  
3/4/202112/31/2020$0.12($0.16)($0.28)($0.16)$9.30 million$9.92 million  
11/12/2020Q3($0.19)$0.15+$0.34$0.15$7.94 million$9.11 million  
8/6/2020Q2 2020($0.31)($0.05)+$0.26($0.05)$6.47 million$6.31 million  
5/12/2020Q1($0.19)($0.40)($0.21)($0.40)$4.63 million$4.28 million  
3/4/202012/31/2019$0.31$0.20($0.11)$0.20$7.70 million$7.67 million  
11/12/20199/30/2019$0.10$1.97+$1.87($1.97)$5.73 million$20.64 million  
8/8/2019Q2 2019($0.55)$0.31+$0.86$0.31$3.91 million$6.78 million
5/9/20193/31/2019($0.88)($0.44)+$0.44($0.44)$1.90 million$5.44 million  
3/21/20197/31/2018($0.08)($0.37)($0.29)($0.37)$5.20 million$4.76 million  
11/7/2018Q3($0.11)($0.32)($0.21)($0.32)$4.70 million$4.37 million
8/9/2018Q2 2018($1.07)($0.52)+$0.55($0.52)$2.10 million$3.15 million
5/8/2018Q1 2018($0.29)($3.68)($3.39)($3.68)$2.00 million$1.70 million
12/4/2017Q1 2018($1.19)($2.77)($1.58)($2.77)$0.02 million
10/13/2017Q4 2017($0.87)($0.17)+$0.70($0.17)$3.77 million
6/14/2017Q3 2017($0.82)($1.55)($0.73)($1.55)$0.02 million
3/16/2017Q2 2017($0.85)$4.91+$5.76$4.91$13.54 million
12/16/2016Q1 2017($1.14)($0.30)+$0.84($0.30)$0.70 million$1.12 million
10/31/2016Q4 2016($0.52)($0.52)($0.52)$0.10 million$0.31 million
6/8/2016Q3 2016$0.15+$0.15$0.15$2.61 million
3/15/2016Q2 2016$1.52+$1.52$1.52$6.86 million
8/7/2012$0.19$0.21+$0.02
5/14/2012$0.20$0.21+$0.01
2/7/2012$0.29$0.26($0.03)  
11/9/2011$0.24$0.24
8/2/2011$0.15$0.21+$0.06
5/9/2011$0.19$0.20+$0.01  
1/27/2011$0.16$0.23+$0.07












Opiant Pharmaceuticals Earnings - Frequently Asked Questions

How much revenue does Opiant Pharmaceuticals generate each year?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a recorded annual revenue of $47.78 million.

How much profit does Opiant Pharmaceuticals generate each year?

Opiant Pharmaceuticals (NASDAQ:OPNT) has a recorded net income of $3.01 million. OPNT has generated -$6.56 earnings per share over the last four quarters.

What is Opiant Pharmaceuticals's EPS forecast for next year?

Opiant Pharmaceuticals's earnings are expected to grow from ($8.10) per share to ($3.34) per share in the next year.

More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:OPNT) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -